<DOC>
	<DOCNO>NCT02749071</DOCNO>
	<brief_summary>The purpose investigation demonstrate safety effectiveness Lower Esophageal Sphincter ( LES ) Stimulation System treat gastroesophageal reflux disease ( GERD ) . This investigation multicenter , randomize , double-blind , sham-controlled study . After implant procedure , subject randomize either Treatment Group ( immediate stimulation ) Control Group ( delay stimulation ) six month follow additional open-label phase subject receive electrical stimulation . Subjects continue stimulation treatment extend open-label follow-up phase 5 year post-stimulation .</brief_summary>
	<brief_title>An Investigation EndoStim® Lower Esophageal Sphincter ( LES ) Stimulation System Treatment Reflux</brief_title>
	<detailed_description>The purpose investigation demonstrate safety effectiveness EndoStim® Lower Esophageal Sphincter ( LES ) Stimulation System treatment subject gastroesophageal reflux disease ( GERD ) . This investigation multicenter , randomize , double-blind , sham-controlled clinical investigation . After implant procedure , subject randomize either Treatment Group ( immediate stimulation ) Control Group ( delay stimulation ) 6-month , double-blind phase follow additional open-label treatment phase subject receive electrical stimulation therapy total 12 month . Subjects continue stimulation treatment extend open-label follow-up phase include 18 month post-stimulation phone interview follow annual visit 5 year post-stimulation .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<criteria>1 . Able willing provide write informed consent 2 . Able willing comply require study procedure followup schedule 3 . 22 75 year age time inform consent 4 . Documented symptom gastroesophageal reflux disease ( GERD ) longer 6 month ( regurgitation and/or heartburn define burn epigastric substernal pain responds acid neutralization suppression ) require daily use proton pump inhibitor ( PPIs ) antireflux drug therapy , continue symptom despite maximum medical therapy `` intolerant '' severe sideeffects ( e.g . anaphylaxis severe allergic reaction , recurrent C. difficile , severe hypomagnesaemia ) one PPI mild/moderate side effect ( e.g . nausea , vomit , diarrhea abdominal pain ) least 2 PPIs different chemical class . 5 . Symptomatic improvement PPI therapy demonstrate composite GERDhealthrelated quality life ( HRQL ) score ≥20 PPI , ≥10 point improvement PPI compare PPI composite GERDHRQL score . Patients meet definition PPI intolerant require ≥10 point improvement . The onPPI score satisfy criterion score GERDHRQL assessment complete resume PPIs follow Baseline visit . 6 . Excessive low esophageal acid exposure pH monitoring ( defined distal esophageal pH &lt; 4 &gt; 6.0 % monitoring time ) perform least 5 day PPIs least 2 day H2 blocker . At least 18 hour esophageal pH record consider adequate inclusion base day ( least 18 hour valid data ) high acid exposure percentage time . 7 . Esophagitis ≤ Grade B ( Los Angeles ( LA ) classification ) measure upper endoscopy PPI H2 blocker 1014 day 8 . Esophageal body contraction amplitude &gt; 30 mmHg &gt; 30 % swallow &gt; 30 % peristaltic contraction HRM ≥ 30 % peristaltic contraction DCI &gt; 450 . 9 . Suitable surgical candidate able undergo general anesthesia laparoscopic surgery 1 . Previous EndoStim LES System implant and/or implant attempt 2 . Previous surgery involve gastroesophageal junction lead implant site , Nissen fundoplication 3 . Previous endoscopic intervention treatment GERD and/or Barrett 's esophagus 4 . Hiatal hernia large 3 cm determine endoscopy 5 . History gastroparesis 6 . Any nonGERD esophageal motility disorder opinion investigator precludes antireflux procedure 7 . History known esophageal stricture significant esophageal anatomic abnormality ( obstructive lesion , etc . ) 8 . Barrett 's esophagus grade dysplasia 9 . Documented history esophagitis Grade C D ( LA Classification ) 10 . History suspect confirmed esophageal gastric cancer 11 . Esophageal gastric varix 12 . Symptoms dysphagia per week every week within last 3 month 13 . Unable tolerate withdrawal H2 Blockers PPI medication 14 . Suspected known allergy titanium , platinum , iridium , stainless steel , silicone , epoxy , nylon 15 . Body mass index ( BMI ) &gt; 35 kg/m2 16 . Any significant multisystem diseases 17 . Autoimmune connective tissue disorder ( scleroderma , dermatomyositis , CalcinosisRaynaud'sEsophagus Sclerodactyly Syndrome ( CREST ) , Sjogren 's Syndrome , Sharp 's Syndrome , etc . ) require therapy precede 2 year 18 . Type 1 diabetes mellitus uncontrolled Type 2 diabetes mellitus ( T2DM ) define HbA1c &gt; 9.5 previous 6 month screening/baseline 19 . Significant cardiac arrhythmia ectopy significant cardiovascular disease ( i.e . unstable angina pectoris , hemodynamically significant valvular disease , severe congestive heart failure ) , cardiac therapeutic intervention within last 6 month . 20 . Significant cerebrovascular event within last 6 month 21 . Existing implanted electrical stimulator ( pacemaker , implantable cardioverter defibrillator , deep brain stimulator ( DBS ) , bone growth pelvic floor stimulators , drug pump , etc . ) 22 . Female subject childbearing potential pregnant nursing , intend become pregnant trial period , use reliable form birth control 23 . Currently enrol potentially confound research 24 . Active infection determine investigator 25 . History malignancy , basal cell carcinoma , last 2 year 26 . Life expectancy le 3 year aa . Diagnosed major psychiatric disorder ( bipolar , schizophrenia , etc . ) bb . Any condition , discretion investigator sponsor , would interfere accurate interpretation study endpoint preclude participation trial</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>